Table 2.

Summary of in vitro stimulation experiment and IFN-γ ELISPOT results

Experiment no.WT1DR 328
WT1DR 423
WT1DR 122
WT1DR 122A1
Donor HLADRB*ResponseDonor HLADRBResponseDonor HLADRBResponseDonor HLADRBResponse
11001/1501+++1001/1501+++1401/15XX1401/15XX+ (heteroclitic)
2301/901+++101/12011401+1401++ (heteroclitic)
31001/1501++1001/15011401+1401+ (heteroclitic)
4407/1302NA§407/1302NA104/1104104/1104+++ (heteroclitic)
5407/1302+++407/1302+405/1302301/1601NA
61001/15011001/1501301/1601++405/1302
7407/1302407/13021401/15XX+++15XX+++ (heteroclitic)
81001/1501++1001/150115XX+422/13XX+++ (heteroclitic)
9407/1302++407/1302+1401/15XX+++422/13XX++ (heteroclitic)
10701/1202++701/1202301/1601
111401/15XX++1401/15XX1401/15XX+
12407/1302+++422/13XX1401/15XX+
13422/13XX+422/13XX+++15XX+++ (heteroclitic)
14422/13XX+++1001/1501+++
151001/1501+++
No. donors680%635.7%666.6%776.9%
  • * Healthy donor CD3+/CD4+ T cells were stimulated twice with individual WT1 peptide as described in Materials and Methods. Stimulated T cells were challenged in an IFN-γ ELISPOT.

  • ELISPOT results comparing T cell reactivity with autologous CD14+ cells pulsed with stimulating peptide versus autologous CD14+ cells pulsed with irrelevant peptide. −, negative results; +, two times background; ++, three times background; +++, four times background.

  • T cells stimulated with WT1DR peptide 122A1 recognized CD14+ cells pulsed with stimulating peptide and CD14+ cells pulsed with WT1DR peptide 122.

  • § Experiment failed.

  • Percentage of experiments with a significant positive results (P ≤ 0.05).